• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用 COVID-19 特异性模型计算无症状感染者以估计群体免疫阈值。

Estimating the herd immunity threshold by accounting for the hidden asymptomatics using a COVID-19 specific model.

机构信息

Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore, India.

Indian Institute of Science, Bengaluru, India.

出版信息

PLoS One. 2020 Dec 16;15(12):e0242132. doi: 10.1371/journal.pone.0242132. eCollection 2020.

DOI:10.1371/journal.pone.0242132
PMID:33326421
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7744057/
Abstract

A quantitative COVID-19 model that incorporates hidden asymptomatic patients is developed, and an analytic solution in parametric form is given. The model incorporates the impact of lock-down and resulting spatial migration of population due to announcement of lock-down. A method is presented for estimating the model parameters from real-world data, and it is shown that the various phases in the observed epidemiological data are captured well. It is shown that increase of infections slows down and herd immunity is achieved when active symptomatic patients are 10-25% of the population for the four countries we studied. Finally, a method for estimating the number of asymptomatic patients, who have been the key hidden link in the spread of the infections, is presented.

摘要

我们建立了一个包含隐性无症状患者的定量 COVID-19 模型,并给出了参数形式的解析解。该模型纳入了封锁措施的影响以及因封锁措施宣布而导致的人口的空间迁移。提出了一种从实际数据中估计模型参数的方法,并表明该方法能够很好地捕捉到观察到的流行病学数据中的各个阶段。结果表明,当四个国家中活跃的有症状患者占人口的 10-25%时,感染的增长率会减缓,并实现群体免疫。最后,提出了一种估计无症状患者数量的方法,无症状患者一直是感染传播的关键隐性环节。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/b592338c045c/pone.0242132.g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/a1a4479910de/pone.0242132.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/ea11fb5afc5b/pone.0242132.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/12769c877d58/pone.0242132.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/bc0e8daba016/pone.0242132.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/b29863abf1c0/pone.0242132.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/941907799816/pone.0242132.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/26765b2858be/pone.0242132.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/faa8849ea684/pone.0242132.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/95168cd4c9a1/pone.0242132.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/55769006f665/pone.0242132.g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/b592338c045c/pone.0242132.g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/a1a4479910de/pone.0242132.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/ea11fb5afc5b/pone.0242132.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/12769c877d58/pone.0242132.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/bc0e8daba016/pone.0242132.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/b29863abf1c0/pone.0242132.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/941907799816/pone.0242132.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/26765b2858be/pone.0242132.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/faa8849ea684/pone.0242132.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/95168cd4c9a1/pone.0242132.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/55769006f665/pone.0242132.g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe5/7744057/b592338c045c/pone.0242132.g011.jpg

相似文献

1
Estimating the herd immunity threshold by accounting for the hidden asymptomatics using a COVID-19 specific model.利用 COVID-19 特异性模型计算无症状感染者以估计群体免疫阈值。
PLoS One. 2020 Dec 16;15(12):e0242132. doi: 10.1371/journal.pone.0242132. eCollection 2020.
2
Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021.2021 年 5 月波兰人群中对 SARS-CoV-2 具有免疫力的隐匿人群。
PLoS One. 2022 Feb 3;17(2):e0253638. doi: 10.1371/journal.pone.0253638. eCollection 2022.
3
[Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].[意大利北部皮埃蒙特大区博尔戈塞西亚人群中抗SARS-CoV-2 IgG/IgM抗体的血清流行率:封锁后时期的监测策略?]
Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):200-206. doi: 10.19191/EP20.5-6.S2.119.
4
Model based estimation of the SARS-CoV-2 immunization level in austria and consequences for herd immunity effects.基于模型的奥地利 SARS-CoV-2 免疫水平估计及其对群体免疫效果的影响。
Sci Rep. 2022 Feb 21;12(1):2872. doi: 10.1038/s41598-022-06771-x.
5
Dynamical Evolution of COVID-19 in Italy With an Evaluation of the Size of the Asymptomatic Infective Population.意大利 COVID-19 的动态演变及无症状感染人群规模评估
IEEE J Biomed Health Inform. 2021 Apr;25(4):1326-1332. doi: 10.1109/JBHI.2020.3009038. Epub 2021 Apr 6.
6
Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses.无症状 SARS-CoV-2 感染病例的血清学调查显示,抗体反应较弱且逐渐减弱。
Emerg Microbes Infect. 2021 Dec;10(1):905-912. doi: 10.1080/22221751.2021.1919032.
7
SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic.新冠疫情期间俄罗斯人群的新冠病毒血清流行率结构
Viruses. 2021 Aug 19;13(8):1648. doi: 10.3390/v13081648.
8
Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease Under Biologic Treatment.接受生物治疗的炎症性肠病患者中的无症状严重急性呼吸综合征冠状病毒2感染
Gastroenterology. 2020 Dec;159(6):2229-2231.e2. doi: 10.1053/j.gastro.2020.08.046. Epub 2020 Aug 26.
9
How to Understand Herd Immunity in the Context of COVID-19.如何理解 COVID-19 大流行中的群体免疫。
Viral Immunol. 2021 Apr;34(3):174-181. doi: 10.1089/vim.2020.0195. Epub 2020 Dec 21.
10
Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity.感染 SARS-CoV-2 期间出现 COVID-19 症状定义了体液免疫的衰减。
Front Immunol. 2021 Aug 16;12:722027. doi: 10.3389/fimmu.2021.722027. eCollection 2021.

引用本文的文献

1
Key Attributes and Clusters of the Korean Exercise Healthcare Industry Viewed through Big Data: Comparison before and after the COVID-19 Pandemic.通过大数据视角看韩国运动保健产业的关键属性与集群:新冠疫情前后的比较
Healthcare (Basel). 2023 Jul 26;11(15):2133. doi: 10.3390/healthcare11152133.
2
The Transmission Dynamics of a Compartmental Epidemic Model for COVID-19 with the Asymptomatic Population via Closed-Form Solutions.具有无症状人群的COVID-19 compartmental流行模型通过闭式解的传播动力学
Vaccines (Basel). 2022 Dec 16;10(12):2162. doi: 10.3390/vaccines10122162.
3
Epidemiological challenges in pandemic coronavirus disease (COVID-19): Role of artificial intelligence.

本文引用的文献

1
COVID-19 antibody seroprevalence in Santa Clara County, California.加利福尼亚州圣克拉拉县的新冠病毒抗体血清流行率。
Int J Epidemiol. 2021 May 17;50(2):410-419. doi: 10.1093/ije/dyab010.
2
Minimal and adaptive numerical strategy for critical resource planning in a pandemic.大流行期间关键资源规划的最小化和自适应数值策略。
Phys Rev E. 2020 Aug;102(2-1):021301. doi: 10.1103/PhysRevE.102.021301.
3
A study on infectivity of asymptomatic SARS-CoV-2 carriers.无症状 SARS-CoV-2 携带者的传染性研究。
大流行冠状病毒病(COVID-19)中的流行病学挑战:人工智能的作用
Wiley Interdiscip Rev Data Min Knowl Discov. 2022 Jul-Aug;12(4):e1462. doi: 10.1002/widm.1462. Epub 2022 Jun 28.
4
Knowledge, Attitudes and Practices towards SARS-CoV-2 vaccination among morbid obese individuals: a pilot study.肥胖人群对 SARS-CoV-2 疫苗接种的知识、态度和实践:一项初步研究。
Acta Biomed. 2022 Jul 1;93(3):e2022234. doi: 10.23750/abm.v93i3.12386.
5
Estimates of Presumed Population Immunity to SARS-CoV-2 by State in the United States, August 2021.2021年8月美国各州对新冠病毒假定人群免疫力的估计。
Open Forum Infect Dis. 2022 Jan 17;9(2):ofab647. doi: 10.1093/ofid/ofab647. eCollection 2022 Feb.
6
Mandate or Not Mandate: Knowledge, Attitudes, and Practices of Italian Occupational Physicians towards SARS-CoV-2 Immunization at the Beginning of Vaccination Campaign.强制接种还是不强制接种:疫苗接种运动开始时意大利职业医生对SARS-CoV-2免疫接种的知识、态度和做法
Vaccines (Basel). 2021 Aug 11;9(8):889. doi: 10.3390/vaccines9080889.
7
High seroprevalence for SARS-CoV-2 infection in South America, but still not enough for herd immunity!南美洲 SARS-CoV-2 感染血清阳性率高,但仍未达到群体免疫水平!
Int J Infect Dis. 2021 Aug;109:244-246. doi: 10.1016/j.ijid.2021.07.022. Epub 2021 Jul 11.
8
Dynamical characterization of antiviral effects in COVID-19.新型冠状病毒肺炎抗病毒作用的动力学特征
Annu Rev Control. 2021;52:587-601. doi: 10.1016/j.arcontrol.2021.05.001. Epub 2021 May 28.
9
Modelling a pandemic with asymptomatic patients, impact of lockdown and herd immunity, with applications to SARS-CoV-2.针对无症状患者对大流行进行建模、封锁和群体免疫的影响及其在严重急性呼吸综合征冠状病毒2(SARS-CoV-2)中的应用
Annu Rev Control. 2020;50:432-447. doi: 10.1016/j.arcontrol.2020.10.003. Epub 2020 Oct 9.
Respir Med. 2020 Aug;169:106026. doi: 10.1016/j.rmed.2020.106026. Epub 2020 May 13.
4
Herd Immunity: Understanding COVID-19.群体免疫:了解 COVID-19。
Immunity. 2020 May 19;52(5):737-741. doi: 10.1016/j.immuni.2020.04.012.
5
Serological tests facilitate identification of asymptomatic SARS-CoV-2 infection in Wuhan, China.血清学检测有助于在中国武汉识别无症状的新冠病毒感染。
J Med Virol. 2020 Oct;92(10):1795-1796. doi: 10.1002/jmv.25904. Epub 2020 Jun 24.
6
Temporal dynamics in viral shedding and transmissibility of COVID-19.新冠病毒脱落和传播的时间动态。
Nat Med. 2020 May;26(5):672-675. doi: 10.1038/s41591-020-0869-5. Epub 2020 Apr 15.
7
Special report: The simulations driving the world's response to COVID-19.特别报道:推动全球应对新冠疫情的模拟分析
Nature. 2020 Apr;580(7803):316-318. doi: 10.1038/d41586-020-01003-6.
8
Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries.群体免疫——评估受影响国家遏制新冠疫情所需的群体免疫水平。
J Infect. 2020 Jun;80(6):e32-e33. doi: 10.1016/j.jinf.2020.03.027. Epub 2020 Mar 21.
9
Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2).大量未记录的感染使新型冠状病毒(SARS-CoV-2)迅速传播。
Science. 2020 May 1;368(6490):489-493. doi: 10.1126/science.abb3221. Epub 2020 Mar 16.
10
Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19).新型冠状病毒感染(COVID-19)无症状感染率的估计。
Int J Infect Dis. 2020 May;94:154-155. doi: 10.1016/j.ijid.2020.03.020. Epub 2020 Mar 14.